Rigel Pharmaceuticals Inc
RIGL35.110USD
+0.890+2.60%
收盘 09/18, 16:00（美东）报价延迟15分钟
629.77M总市值
6.44市盈率 TTM
关于 Rigel Pharmaceuticals Inc 公司
Rigel Pharmaceuticals, Inc. 是一家生物技术公司。该公司致力于开发和提供新型疗法，以显著改善血液病和癌症患者的生活。该公司专注于解决对疾病机制至关重要的信号通路的产品。其首款产品是 TAVALISSE（福他替尼二钠六水合物）片剂，这是一种经批准的口服脾酪氨酸激酶抑制剂，用于治疗对先前治疗反应不足的慢性免疫性血小板减少症 (ITP) 成人患者。其第二款产品是 REZLIDHIA（奥鲁他尼）胶囊，用于治疗经 FDA 批准的检测检测出易感异柠檬酸脱氢酶-1 (IDH1) 突变的复发或难治性 (R/R) 急性髓细胞白血病 (AML) 成人患者。其产品 GAVRETO（pralsetinib）是一种每日一次的小分子口服激酶抑制剂，用于抑制转染过程中重排的野生型 RET 和致癌 RET 融合。
公司简介
公司代码RIGL
公司名称Rigel Pharmaceuticals Inc
上市日期Nov 29, 2000
CEOMr. Raul R. Rodriguez
员工数量162
证券类型Ordinary Share
年结日Nov 29
公司地址- -
城市- -
上市交易所NASDAQ Global Select Consolidated
国家- -
邮编- -
电话- -
网址- -
公司代码RIGL
上市日期Nov 29, 2000
CEOMr. Raul R. Rodriguez
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
9.38K
+36.36%
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Raymond J. Furey
Mr. Raymond J. Furey
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Raul R. Rodriguez
Mr. Raul R. Rodriguez
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
239.45K
-3.76%
Mr. Dean L. Schorno, CPA
Mr. Dean L. Schorno, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.23K
-6.18%
Mr. David A. Santos
Mr. David A. Santos
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
51.70K
-7.05%
Dr. Lisa Rojkjaer, M.D.
Dr. Lisa Rojkjaer, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
19.72K
--
Dr. Walter H. Moos, Ph.D.
Dr. Walter H. Moos, Ph.D.
Independent Director
Independent Director
12.72K
+24.46%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
12.50K
+25.00%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Armistice Capital LLC
8.92%
Morgan Stanley & Co. LLC
8.25%
BlackRock Institutional Trust Company, N.A.
7.85%
The Vanguard Group, Inc.
5.87%
Soleus Capital Management, L.P.
3.67%
其他
65.45%
持股股东
持股股东
占比
Armistice Capital LLC
8.92%
Morgan Stanley & Co. LLC
8.25%
BlackRock Institutional Trust Company, N.A.
7.85%
The Vanguard Group, Inc.
5.87%
Soleus Capital Management, L.P.
3.67%
其他
65.45%
股东类型
持股股东
占比
Investment Advisor
29.38%
Investment Advisor/Hedge Fund
23.07%
Hedge Fund
16.28%
Research Firm
10.35%
Individual Investor
2.65%
Pension Fund
0.76%
Bank and Trust
0.14%
Insurance Company
0.04%
其他
17.33%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
290
14.23M
79.32%
-22.43K
2025Q1
295
14.90M
83.36%
+888.64K
2024Q4
281
12.77M
72.51%
-849.60K
2024Q3
291
12.41M
70.53%
-421.54K
2024Q2
303
10.88M
61.98%
-2.99M
2024Q1
319
11.57M
65.99%
-3.84M
2023Q4
326
11.03M
63.24%
-4.70M
2023Q3
343
11.50M
66.01%
-5.45M
2023Q2
356
11.96M
68.88%
-4.98M
2023Q1
359
12.15M
69.98%
-5.32M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Armistice Capital LLC
1.52M
8.48%
+364.00K
+31.60%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.48M
8.28%
-54.14K
-3.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.47M
8.23%
-33.13K
-2.20%
Mar 31, 2025
The Vanguard Group, Inc.
1.03M
5.75%
+15.14K
+1.49%
Mar 31, 2025
Soleus Capital Management, L.P.
1.13M
6.33%
--
--
Mar 31, 2025
Acadian Asset Management LLC
565.04K
3.16%
+188.68K
+50.13%
Mar 31, 2025
State Street Global Advisors (US)
637.03K
3.56%
+256.52K
+67.41%
Mar 31, 2025
Capitolis Liquid Global Markets LLC
693.10K
3.88%
+693.10K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
411.17K
2.3%
+9.12K
+2.27%
Mar 31, 2025
Marshall Wace LLP
211.75K
1.18%
+211.75K
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
Invesco Nasdaq Biotechnology ETF
0.07%
Franklin US Small Cap Multifactor Index ETF
0.05%
Innovator US Small Cap Managed Floor ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
0.04%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
Avantis Responsible US Equity ETF
0.01%
Pacer US Small Cap Cash Cows ETF
0%
查看更多
Invesco Nasdaq Biotechnology ETF
占比0.07%
Franklin US Small Cap Multifactor Index ETF
占比0.05%
Innovator US Small Cap Managed Floor ETF
占比0.04%
ProShares Ultra Nasdaq Biotechnology
占比0.04%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.04%
ProShares Hedge Replication ETF
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
Avantis Responsible US Equity ETF
占比0.01%
Pacer US Small Cap Cash Cows ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
公告日期
类型
比率
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
Jun 25, 2024
Merger
10→1
